Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

-------------- 13,762 19,553 ------------------------------------------------------------------------- Loss from operations (7,340) (13,442) ------------------------------------------------------------------------- Other income Interest income 58 154 Foreign exchange gain 1,402 900 ------------------------------------------------------------------------- 1,460 1,054 ------------------------------------------------------------------------- Net loss for the period (5,880) (12,388) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net loss per share Basic and diluted (0.09) (0.23) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of shares Basic and diluted 63,089,954 53,187,470 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Interim Consolidated Balance Sheet Information (in thousands) (unaudited) ------------------------------------------------------------------------- As at As at March 31, December 31, 2010 2009 ------------------------------------------------------------------------- ----------------------------
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... methods to scout the human genome,s repetitive landscapes, ... These advances, as reported today in Science ... in the number and content of repeated DNA segments. ... the normal diversity among people. Copy number variations might ...
... Health Minister and scientist, General Vsevolod Ogarkov, had no idea ... by 21st century American doctors and patients for immune ... Dr. Ogarkov,s team were the first researchers to successfully modify ... The probiotic-derived supplement Del-Immune V (R) is ...
... PDL BioPharma, Inc. (PDL, the Company) (Nasdaq: ... privately negotiated exchange agreements under which it will retire $92.0 ... Senior Notes due February 15, 2012 (the 2012 Notes).  Pursuant ... will receive $92.0 million in aggregate principal of new 2.875% ...
Cached Biology Technology:New methods detect subtleties in human genomes' repetitive landscapes 2New methods detect subtleties in human genomes' repetitive landscapes 3Cold War Probiotic Discovery Now a Weapon in American Cold & Flu War 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 2PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 3
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... per week increased the risk of developing pancreatic cancer by ... drinks, according to a report in Cancer Epidemiology, Biomarkers ... Cancer Research. Although relatively rare, pancreatic cancer remains ... people who are diagnosed are alive five years later. ...
... that inhibits serotonin synthesis in the gut, administered orally once ... international team led by researchers from Columbia University Medical Center, ... Serotonin in the gut has been shown in recent research ... therapies that build new bone; most current drugs for osteoporosis ...
... , , , ... a leading provider of iris-based biometric identification technology, products and ... I Supplemental Report as the most accurate iris technology for ... next best competitor exhibits error rates approximately 50% higher than ...
Cached Biology News:Soft drink consumption may increase risk of pancreatic cancer 2Inhibiting serotonin in gut could cure osteoporosis 2Inhibiting serotonin in gut could cure osteoporosis 3NIST Supplemental Testing Re-confirms IriTech is #1 Iris Identification Provider 2
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... ultimate tool for both microplate reader ... two editions of SkanIt Software available; ... in life science research, and a ... for compliance with FDA's 21 CFR ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Biology Products: